{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:09:49Z","timestamp":1792026589146,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Interleukin (IL)\u201023p19 and IL\u201017 inhibitors have demonstrated high efficacy for psoriasis in randomized controlled trials, though real\u2010world data, particularly for risankizumab (IL\u201023p19 inhibitor) and brodalumab (IL\u201017 receptor (IL\u201017R) inhibitor), is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess drug survival of IL\u201023p19 and IL\u201017 inhibitors compared to other biologics for psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from November 2007 to June 2023. Multivariable flexible parametric models assessed drug survival, with discontinuation due to ineffectiveness and adverse effects reported separately. The primary outcome measure was the absolute difference in restricted mean survival time at 2\u2009years, referred to as adjusted survival time, between all comparators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 19,034 treatment courses (median follow\u2010up: 2.3\u2009years), treatments included adalimumab (tumour necrosis factor\u2010alpha (TNF\u2010a) inhibitor, <jats:italic>n<\/jats:italic>\u2009=\u20096,815), ustekinumab (IL\u201012\/23p40 inhibitor, <jats:italic>n<\/jats:italic>\u2009=\u20095,639), secukinumab (IL\u201017A inhibitor, <jats:italic>n<\/jats:italic>\u2009=\u20093,051), ixekizumab (IL\u201017A inhibitor, <jats:italic>n<\/jats:italic>\u2009=\u20091,072), brodalumab (<jats:italic>n<\/jats:italic>\u2009=\u2009367), guselkumab (IL\u201023p19 inhibitor, <jats:italic>n<\/jats:italic>\u2009=\u20091,258) and risankizumab (<jats:italic>n<\/jats:italic>\u2009=\u2009832).<\/jats:p><jats:p>Guselkumab and risankizumab had the highest adjusted survival times (years [interquartile ranges]) for effectiveness (1.93 [1.91\u20131.95] and 1.93 [1.90\u20131.96], respectively). Risankizumab had the highest survival for safety (1.94 [1.92\u20131.96]) followed by guselkumab (1.92 [1.90\u20131.94]) and ustekinumab (1.92 [1.91\u20131.93]). Brodalumab showed lower adjusted survival time for effectiveness (1.75 [1.69\u20131.81]) than most biologics except secukinumab and adalimumab; and similar survival for safety (1.85 [1.81\u20131.90]) compared to IL\u201017A inhibitors and adalimumab. In patients with psoriatic arthritis, ustekinumab showed reduced drug survival. Prior biologic exposure was associated with a dose\u2013response reduction in survival which was significantly larger for IL\u201017 inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Guselkumab and risankizumab have the most favourable drug survival for effectiveness, with comparable safety to ustekinumab, and more favourable than other BADBIR biologics. Longer drug survival may reduce treatment burden by minimizing treatment switches, clinic visits and disease flares, supporting IL\u201023p19 inhibitors as a practical long\u2010term option for psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.20739","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T08:50:53Z","timestamp":1748508653000},"page":"1785-1795","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Drug survival of IL\u201023 and IL\u201017 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7352-6454","authenticated-orcid":false,"given":"Leila","family":"Motedayen Aval","sequence":"first","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z. N.","family":"Yiu","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-0781","authenticated-orcid":false,"given":"Oras A.","family":"Alabas","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-4427","authenticated-orcid":false,"given":"Christopher E. M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"},{"name":"Department of Dermatology, King's College Hospital King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust Institute of Translational and Clinical Medicine, Medical School, Newcastle University  Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Hampton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust Institute of Translational and Clinical Medicine, Medical School, Newcastle University  Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, and King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester The Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BADBIR Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0183"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000488586"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2909"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2133531"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00598-4"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad113.125"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041675"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1196966"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00422-w"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.048"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17104"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10835.x"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13908"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17738"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1203"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6553"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2250"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100297"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15251"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2082354"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00722-y"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02028-1"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:40:53Z","timestamp":1759218053000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/jdv.20739"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20739","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"2024-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}